Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in F...( Long-term debt ...),Health

Long-term debt 6,037 6,675

Other long-term liabilities 1,814 4,395

Stockholders' equity 494,188 479,648

Total liabilities & equity $597,756 $572,735

FREE CASH FLOW RECONCILIATION

FREE CASH FLOW RECONCILIATION: Three Months Ended Twelve Months Ended

3-29-08 3-31-07 3-29-08 3-31-07

GAAP CASH FLOW FROM OPERATIONS $30,414 $24,096 $76,168 $83,563

Capital expenditures ($16,223) ($13,453) ($56,800) ($40,438)

Proceeds from sale of property,

plant and equipment $605 $255 $1,834 $2,843

Net investment in property,

plant and equipment ($15,618) ($13,198) ($54,966) ($37,595)

Free Cash Flow $14,796 $10,898 $21,202 $45,968

RECONCILIATION OF NON-GAAP MEASURES

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.

These measures are used by management to monitor the financial performance of the business, inform business decision making, and to forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below we have removed restructuring costs from our GAAP expenses. These restructuring costs result from a sign
'/>"/>